PMID- 29145880
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20181113
IS  - 1742-2094 (Electronic)
IS  - 1742-2094 (Linking)
VI  - 14
IP  - 1
DP  - 2017 Nov 16
TI  - Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly 
      associates to HLA-DRB15.
PG  - 224
LID - 10.1186/s12974-017-0996-1 [doi]
LID - 224
AB  - BACKGROUND: The aim of the research is to study the human leukocyte antigen (HLA) 
      class II allele frequencies in chronic inflammatory demyelinating 
      polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) 
      antibodies. METHODS: Thirteen anti-NF155+ and 35 anti-NF155 negative 
      (anti-NF155neg) CIDP patients were included in a case-control study. The 
      frequencies of the DRB1 HLA allele were analyzed in all patients while DQ 
      frequencies were only studied in patients sharing the DRB1*15 allele. In silico 
      HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze 
      overlap between presented peptides and antigenic regions. RESULTS: DRB1*15 
      alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP 
      patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, 
      CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher 
      proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, 
      CI = 4.434 to 57.30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg 
      CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ 
      CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 
      allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding 
      to DRB1*15 alleles showed significant overlap in the peptides presented by the 
      15:01 and 15:02 alleles, suggesting functional homology. CONCLUSIONS: DRB1*15 
      alleles are the first strong risk factor associated to a CIDP subset, providing 
      additional evidence that anti-NF155+ CIDP patients constitute a differentiated 
      disease within the CIDP syndrome.
FAU - Martinez-Martinez, Laura
AU  - Martinez-Martinez L
AD  - Immunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma 
      de Barcelona, Barcelona, Spain.
FAU - Lleixa, Ma Cinta
AU  - Lleixa MC
AD  - Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i 
      Sant Pau, Universitat Autonoma de Barcelona, Mas Casanovas 90, 08041, Barcelona, 
      Spain.
AD  - Centro para la Investigacion Biomedica en Red en Enfermedades Raras, CIBERER, 
      Madrid, Spain.
FAU - Boera-Carnicero, Gemma
AU  - Boera-Carnicero G
AD  - Immunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma 
      de Barcelona, Barcelona, Spain.
FAU - Cortese, Andrea
AU  - Cortese A
AD  - IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.
AD  - MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and 
      Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK.
FAU - Devaux, Jerome
AU  - Devaux J
AD  - Centre de Recherche en Neurobiologie et Neurophysiologie de Marseille - CRN2M, 
      UMR 7286, CNRS, Aix-Marseille Universite, Marseille, France.
FAU - Siles, Ana
AU  - Siles A
AD  - Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i 
      Sant Pau, Universitat Autonoma de Barcelona, Mas Casanovas 90, 08041, Barcelona, 
      Spain.
AD  - Centro para la Investigacion Biomedica en Red en Enfermedades Raras, CIBERER, 
      Madrid, Spain.
FAU - Rajabally, Yusuf
AU  - Rajabally Y
AD  - Regional Neuromuscular Clinic, Queen Elizabeth Hospital, University Hospitals of 
      Birmingham, Birmingham, UK.
FAU - Martinez-Pineiro, Alicia
AU  - Martinez-Pineiro A
AD  - Neurology Department, Hospital Germans Trias i Pujol, Universitat Autonoma de 
      Barcelona, Badalona, Spain.
FAU - Carvajal, Alejandra
AU  - Carvajal A
AD  - Department of Neurology, Hospital Virgen de las Nieves, Granada, Spain.
FAU - Pardo, Julio
AU  - Pardo J
AD  - Department of Neurology, Hospital Clinico de Santiago, Santiago de Compostela, 
      Spain.
FAU - Delmont, Emilien
AU  - Delmont E
AD  - Centre de Recherche en Neurobiologie et Neurophysiologie de Marseille - CRN2M, 
      UMR 7286, CNRS, Aix-Marseille Universite, Marseille, France.
AD  - Referral Center for ALS and Neuromuscular Diseases, Timone University Hospital, 
      Aix-Marseille University, Marseille, France.
FAU - Attarian, Shahram
AU  - Attarian S
AD  - Referral Center for ALS and Neuromuscular Diseases, Timone University Hospital, 
      Aix-Marseille University, Marseille, France.
FAU - Diaz-Manera, Jordi
AU  - Diaz-Manera J
AD  - Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i 
      Sant Pau, Universitat Autonoma de Barcelona, Mas Casanovas 90, 08041, Barcelona, 
      Spain.
AD  - Centro para la Investigacion Biomedica en Red en Enfermedades Raras, CIBERER, 
      Madrid, Spain.
FAU - Callegari, Ilaria
AU  - Callegari I
AD  - IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.
AD  - Neuroscience Consortium, Monza Policlinico and Pavia Mondino, University of 
      Pavia, Pavia, Italy.
FAU - Marchioni, Enrico
AU  - Marchioni E
AD  - IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.
FAU - Franciotta, Diego
AU  - Franciotta D
AD  - IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.
FAU - Benedetti, Luana
AU  - Benedetti L
AD  - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and 
      Child Health, University of Genova and IRCCS AOU San Martino-IST, Genoa, Italy.
FAU - Lauria, Guiseppe
AU  - Lauria G
AD  - Neuroalgology Unit, IRCCS Foundation "Carlo Besta" Neurological Institute, Milan, 
      Italy.
AD  - Department of Biomedical and Clinical Sciences "Luigi Sacco", University of 
      Milan, Milan, Italy.
FAU - de la Calle Martin, Oscar
AU  - de la Calle Martin O
AD  - Immunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma 
      de Barcelona, Barcelona, Spain.
FAU - Juarez, Candido
AU  - Juarez C
AD  - Immunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma 
      de Barcelona, Barcelona, Spain.
FAU - Illa, Isabel
AU  - Illa I
AD  - Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i 
      Sant Pau, Universitat Autonoma de Barcelona, Mas Casanovas 90, 08041, Barcelona, 
      Spain.
AD  - Centro para la Investigacion Biomedica en Red en Enfermedades Raras, CIBERER, 
      Madrid, Spain.
FAU - Querol, Luis
AU  - Querol L
AUID- ORCID: 0000-0002-4289-8264
AD  - Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i 
      Sant Pau, Universitat Autonoma de Barcelona, Mas Casanovas 90, 08041, Barcelona, 
      Spain. lquerol@santpau.cat.
AD  - Centro para la Investigacion Biomedica en Red en Enfermedades Raras, CIBERER, 
      Madrid, Spain. lquerol@santpau.cat.
LA  - eng
GR  - PI16/000627/Instituto de Salud Carlos III/
GR  - Paranodal autoimmunity in CIDP: diagnostic and therapeutic value/GBS-CIDP 
      Foundation International/
PT  - Journal Article
DEP - 20171116
PL  - England
TA  - J Neuroinflammation
JT  - Journal of neuroinflammation
JID - 101222974
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*15 antigen)
RN  - 0 (NFASC protein, human)
RN  - 0 (Nerve Growth Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Autoantibodies/immunology
MH  - Autoantigens/immunology
MH  - Case-Control Studies
MH  - Cell Adhesion Molecules/*immunology
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genotype
MH  - HLA-DRB1 Chains/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nerve Growth Factors/*immunology
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/*genetics/*immunology
PMC - PMC5691853
OTO - NOTNLM
OT  - Antibodies
OT  - CIDP
OT  - HLA DRB1*15
OT  - NF155
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Informed consent for study 
      participation was obtained from all patients under protocols approved by the 
      Ethics Committee of the Hospital de la Santa Creu i Sant Pau and local Ethics' 
      Committees/Institutional Boards from all other participating centers. CONSENT FOR 
      PUBLICATION: Not applicable. No individual data, videos, or images from patients 
      are provided. COMPETING INTERESTS: LQ has provided expert testimony and research 
      funds for Grifols and received research funds from Novartis Spain. II provided 
      expert testimony and received speaking fees and travel grants from Pfizer. JD-M 
      provided expert testimony, speaking fees and travel grants for Genzyme. 
      PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2017/11/18 06:00
MHDA- 2018/07/25 06:00
PMCR- 2017/11/16
CRDT- 2017/11/18 06:00
PHST- 2017/10/01 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
PHST- 2017/11/16 00:00 [pmc-release]
AID - 10.1186/s12974-017-0996-1 [pii]
AID - 996 [pii]
AID - 10.1186/s12974-017-0996-1 [doi]
PST - epublish
SO  - J Neuroinflammation. 2017 Nov 16;14(1):224. doi: 10.1186/s12974-017-0996-1.